Related Experiment Video
Updated: Jul 11, 2026
Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
Published on: September 1, 2023
Population pharmacokinetics of valproate in Chinese children with epilepsy
De-Chun Jiang1, Li Wang, Yu-Qin Wang
1Department of Pharmacy, Xuan-wu Hospital of Capital Medical University, Beijing 100053, China.
Insights
A population pharmacokinetic (PPK) model for valproate (VPA) in Chinese epileptic children was developed. This model aids in optimizing anti-epileptic drug use and individualizing treatment regimens for better patient outcomes.
Area of Science:
- Pharmacology
- Pediatric Neurology
- Clinical Pharmacy
Background:
- Epilepsy management in children requires precise dosing of anti-epileptic drugs.
- Valproate (VPA) is a commonly prescribed anti-epileptic medication.
- Population pharmacokinetic (PPK) modeling offers a framework for understanding drug disposition in specific patient populations.
Purpose of the Study:
- To establish a robust population pharmacokinetic (PPK) model for valproate (VPA) in a cohort of Chinese epileptic children.
- To provide a basis for the rational and individualized use of VPA in pediatric epilepsy treatment.
- To improve therapeutic outcomes by optimizing VPA dosage regimens.
Main Methods:
- Utilized sparse serum VPA concentration data from 417 Chinese epileptic children.
- Employed NONMEM software to develop and validate a PPK model, comparing a basic and a final model.
- Assessed model performance using metrics like Mean Prediction Error (MPE) and Root Mean Squared Prediction Error (RMSPE).
Main Results:
- A one-compartment model with first-order absorption best described VPA pharmacokinetics.
- The final PPK model demonstrated superior predictive accuracy compared to the basic model, with significantly lower MPE and RMSPE values.
- Key pharmacokinetic parameters (Ka, V/F, CL/F) were refined in the final model, incorporating covariates like weight and age.
Conclusions:
- Successfully established a population pharmacokinetic (PPK) model for valproate (VPA) in Chinese pediatric epilepsy patients.
- The developed PPK model is a valuable tool for guiding individualized VPA dosage adjustments.
- This research facilitates optimized anti-epileptic drug therapy, potentially enhancing treatment efficacy and safety.
Aim:
The aim of the present study is to establish a population pharmacokinetic (PPK) model of valproate (VPA) in Chinese epileptic children to promote the reasonable use of anti-epileptic drugs.
Methods:
Sparse data of VPA serum concentrations from 417 epileptic children were collected. These patients were divided into 2 groups: the PPK model group (n=317) and the PPK valid group (n=100). The PPK parameter values of VPA were calculated by NONMEM software using the data of the PPK model group. A basic model and a final model were set up. To validate the 2 models, the concentrations of PPK valid group were predicted by each model, respectively. The mean prediction error (MPE), mean squared prediction error (MSPE), root mean squared prediction error (RMSPE), weight residues (WRES), and the 95% confidence intervals (95% CI) were also calculated. Then, the values between the 2 models were compared.
Results:
The PPK of VPA was determined by a 1-compartment model with a first-order absorption process. The basic model was: Ka=3.09 (h(-1)), V/F=20.4 (L), CL/F=0.296 (L/h). The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h). For the basic model, the MPE, MSPE, RMSPE, WRES, and the 95% CI were -23.53 (-30.36, -16.70), 3728.96 (2872.72, 4585.20), 39.62 (34.34, 44.90), and -0.06 (-0.14, 0.02), respectively. For the final model, the MPE, MSPE, RMSPE, WRES, and the 95% CI were -1.16 (-4.85, 2.53), 1002.83 (1050.64, 1143.61), 23.04 (21.12, 24.96), and 0.08 (-0.04, 0.20), respectively. The final model was more optimal than the basic model.
Conclusion:
The PPK model of VPA in Chinese epileptic children was successfully established. It will be valuable to facilitate individualized dosage regimens.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...